Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

Part of paid clinical trials in Nashville, Tennessee.

Sponsor: Janux Therapeutics
Study ID: NCT07813637
Phase: PHASE1
Status: Recruiting

Apply to this trial

Conditions

Castration-Resistant Prostate Cancer (CRPC)
Metastatic Castration-Resistant Prostate Cancer Patients
Metastatic Prostate Cancer
Prostate Cancer

Eligibility Criteria

Sex: MALE
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

JANX013 — DRUG
JANX013 will be administered via IV dosing.
JANX007 — DRUG
JANX007 will be administered via IV dosing.
JANX013 — DRUG
JANX013 will be administered via IV dosing
JANX007 — DRUG
JANX007 will be administered via IV dosing

Study Details

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Key Dates

First listed: Sep 10, 2026
Start date: Sep 10, 2026
Status verified: Sep 2026
Primary completion: Jul 31, 2029
Completion: Jul 31, 2030

Study Design

Enrollment: 110 participants (estimated)
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Arms

Experimental: Dose Escalation
Participants receive JANX013 in combination with JANX007 administered at increasing dose levels per cohort
Experimental: Dose Expansion
Participants receive JANX013 in combination with JANX007. Participants will be dosed at levels previously declared tolerable.